<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065297</url>
  </required_header>
  <id_info>
    <org_study_id>AUDIA-SAMSON HORTON TH17</org_study_id>
    <nct_id>NCT02065297</nct_id>
  </id_info>
  <brief_title>Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)</brief_title>
  <official_title>Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      The aim of this open, controlled, multicentre biomedical research study is to identify new
      markers specifically associated with Horton's disease. This would make it possible to improve
      the diagnosis and management of this disease.

      Participation consists in taking one or several blood samples depending on the group
      patients/controls.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of LTh17 by flow cytometry</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Horton's Disease</condition>
  <condition>Infectious Disease</condition>
  <condition>Neoplasia</condition>
  <condition>Solid Tumor</condition>
  <condition>Hemopathy</condition>
  <arm_group>
    <arm_group_label>Horton's disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoplasia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1 blood sample</intervention_name>
    <arm_group_label>Infectious disease</arm_group_label>
    <arm_group_label>Neoplasia</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)</intervention_name>
    <arm_group_label>Horton's disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Horton' s disease Patients with an infectious disease Patients with neoplasia
        ( solid tumor or hemopathy ) Healthy controls
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients

          -  Patients who have provided written informed consent

          -  Patients with national health insurance cover

          -  Age: 50 to 90 years

        Patients with Horton' s disease :

          -  at the diagnosis, before any treatment

          -  or in remission

          -  or in relapse

        Patients with an infectious disease :

          -  Bacteriologically or radiologically confirmed

          -  Presenting an inflammatory syndrome defined by :

          -  CRP ≥ 10 mg / L

          -  and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1

        Patients with neoplasia ( solid tumour or hemopathy ) :

          -  At the diagnosis, before treatment by chemotherapy

          -  Presenting an inflammatory syndrome defined by:

          -  CRP ≥ 10 mg / L

          -  and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1

        Controls :

        These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary
        hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD (
        Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory,
        or auto-immune disease ( CRP &lt; 5mg / L ) or cancer recruited from the investigating
        departments of Dijon CHU. They will be matched for age and sex.

          -  Age: 18 - 90 years

          -  Patients with national health insurance cover

          -  who have provided written informed consent

          -  Absence of an inflammatory syndrome ( CRP &lt; 5 mg / L )

        Exclusion Criteria :

          -  Any patient who does not meet the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvain AUDIA</last_name>
    <phone>3.80.29.34.32</phone>
    <phone_ext>+33</phone_ext>
    <email>sylvain.audia@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de BESANCON</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine MAGY-BERTRAND</last_name>
      <phone>3 81 66 89 15</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain AUDIA</last_name>
      <phone>3.80.29.34.32</phone>
      <phone_ext>+33</phone_ext>
      <email>sylvain.audia@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de METZ</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MAURIER</last_name>
      <phone>3 87 39 47 72</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

